Profile data is unavailable for this security.
About the company
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The Company offers exceptional healthcare solutions for a wide range of healthcare needs with a diverse portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system (CNS), vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. The Company's subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Broadway Hospitality Services Private Limited, Jaspack Industries Private Limited, and others.
- Revenue in INR (TTM)103.35bn
- Net income in INR19.13bn
- Incorporated1991
- Employees18.47k
- LocationMankind Pharma Ltd262, Okhla Industrial EstateNEW DELHI 110020IndiaIND
- Phone+91 1 146541111
- Fax+91 1 146541382
- Websitehttps://www.mankindpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd | 126.34bn | 15.73bn | 635.35bn | 16.87k | 40.39 | -- | 34.00 | 5.03 | 131.58 | 131.58 | 1,056.65 | -- | -- | -- | -- | 7,488,804.00 | -- | 11.44 | -- | 17.01 | 59.75 | 58.84 | 12.46 | 13.31 | -- | 5.83 | -- | 30.96 | 9.08 | 12.52 | -40.19 | 9.30 | -19.38 | 13.97 |
| Aurobindo Pharma Ltd | 290.02bn | 31.73bn | 715.43bn | 15.69k | 22.56 | 2.40 | 15.25 | 2.47 | 54.12 | 54.12 | 494.54 | 509.35 | 0.6827 | 1.38 | 6.25 | -- | 7.46 | 9.24 | 10.35 | 13.43 | 56.54 | 54.15 | 10.93 | 12.72 | 1.18 | 16.12 | 0.1821 | -- | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | -- |
| Lupin Ltd | 200.11bn | 19.14bn | 730.77bn | 18.97k | 38.28 | 5.11 | 23.33 | 3.65 | 41.89 | 41.89 | 437.85 | 313.60 | 0.8524 | 1.41 | 4.36 | -- | 8.24 | 1.43 | 13.34 | 2.22 | 66.80 | 59.70 | 9.67 | 2.04 | 0.9991 | 8.64 | 0.1689 | 79.28 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Mankind Pharma Ltd | 103.35bn | 19.13bn | 847.12bn | 18.47k | 44.34 | 9.05 | 36.20 | 8.20 | 47.69 | 47.69 | 257.65 | 233.73 | -- | -- | -- | -- | -- | -- | -- | -- | 68.94 | -- | 18.79 | -- | 2.37 | 116.65 | 0.0212 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 107.28bn | 16.56bn | 902.53bn | 13.57k | 54.49 | 13.16 | 36.63 | 8.41 | 48.94 | 48.94 | 317.04 | 202.56 | 0.7135 | 1.19 | 5.66 | -- | 11.01 | 8.34 | 17.25 | 13.03 | 74.96 | 72.01 | 15.44 | 13.17 | 0.6141 | 7.23 | 0.3697 | 53.04 | 11.52 | 6.93 | 32.99 | 30.57 | -8.16 | 26.93 |
| Dr Reddy's Laboratories Ltd | 280.11bn | 55.78bn | 993.39bn | 24.83k | 17.83 | 3.52 | 14.09 | 3.55 | 334.61 | 334.61 | 1,680.33 | 1,696.70 | 0.7874 | 1.46 | 3.67 | -- | 15.68 | 11.37 | 21.05 | 16.02 | 70.69 | 66.52 | 19.91 | 14.63 | 1.92 | 41.27 | 0.0662 | 16.40 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Zydus Lifesciences Ltd | 195.47bn | 38.37bn | 1.06tn | 23.03k | 27.77 | 5.34 | 23.06 | 5.42 | 37.91 | 38.14 | 193.16 | 197.11 | 0.7103 | 1.82 | 4.06 | -- | 13.92 | 9.05 | 19.29 | 14.01 | 68.14 | 62.16 | 19.60 | 14.33 | 1.51 | 22,696.00 | 0.0351 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Divi's Laboratories Ltd | 78.45bn | 16.00bn | 1.17tn | 16.95k | 72.87 | 8.59 | 58.95 | 14.86 | 60.27 | 60.27 | 295.54 | 511.21 | 0.5246 | 1.01 | 3.97 | -- | 10.70 | 16.55 | 11.62 | 18.22 | 60.11 | 57.95 | 20.40 | 26.38 | 5.08 | -- | 0.0002 | 34.33 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Cipla Ltd | 257.74bn | 41.22bn | 1.19tn | 26.62k | 28.99 | 4.47 | 22.94 | 4.63 | 51.02 | 51.02 | 319.08 | 330.77 | 0.829 | 1.70 | 5.84 | -- | 13.37 | 10.09 | 16.16 | 12.40 | 65.78 | 59.69 | 16.12 | 12.66 | 2.71 | 58.30 | 0.0205 | 20.79 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 15 May 2024 | 6.28m | 1.57% |
| Axis Asset Management Co. Ltd.as of 15 May 2024 | 6.17m | 1.54% |
| SBI Funds Management Ltd.as of 30 Apr 2024 | 6.06m | 1.51% |
| The Vanguard Group, Inc.as of 30 Apr 2024 | 3.60m | 0.90% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Mar 2024 | 3.24m | 0.81% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 2.98m | 0.74% |
| Invesco Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 2.48m | 0.62% |
| Canara Robeco Asset Management Co. Ltd.as of 15 May 2024 | 1.94m | 0.49% |
| Tata AIA Life Insurance Co. Ltd.as of 30 Apr 2024 | 1.74m | 0.44% |
| PGIM India Asset Management Pvt Ltd.as of 30 Apr 2024 | 1.54m | 0.38% |
